Dr Reddys Laboratories (RDY) Income from Non-Controlling Interests (2009 - 2026)
Dr Reddys Laboratories (RDY) posted Income from Non-Controlling Interests of -$918960.0 for Q2 2026, down 2200.16% on a QoQ basis from $43756.6 in Q1 2026, and up 4.09% year-over-year from -$882853.0 in Q2 2025.
Analysis
Dr Reddys Laboratories (RDY) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories has reported Income from Non-Controlling Interests for 11 years, with the latest figure at -$918960.0 in Q2 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 4.09% year-over-year to -$918960.0 in Q2 2026; TTM through Jun 2026 was -$4.3 million, a 158.23% decrease from a year earlier, with the FY2026 full-year figure at -$4.4 million, down 152.46% from the prior year.
- Income from Non-Controlling Interests was -$918960.0 for Q2 2026 at Dr Reddys Laboratories, down from $43756.6 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $10.3 million in Q3 2024, with the low at -$2.3 million in Q4 2025.
- Average Income from Non-Controlling Interests over 3 years is $388801.5, with a median of -$938553.2 recorded in 2025.
- The sharpest annual moves came in 2025 and 2026: Income from Non-Controlling Interests tumbled 111.59% in 2025, then soared 105.74% in 2026.
- Over 3 years, Income from Non-Controlling Interests stood at -$1.1 million in 2024, then slumped by 101.6% to -$2.3 million in 2025, then soared by 59.49% to -$918960.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$918960.0 (Q2 2026), $43756.6 (Q1 2026), and -$2.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.58 Bn | 38.93 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.85 Bn | 9.68 Bn | 396.53 Mn | -918,959.97 |
| 4 | Amneal Pharmaceuticals | 5.47 Bn | 5.34 Bn | 334.51 Mn | 11.95 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 526.37 Mn | 2.10 Bn | 2.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 995.08 Mn | 704.96 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 408.84 Mn | 367.59 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 180.35 Mn | 180.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -918,959.97 |
| Mar 31, 2026 | 43,756.64 |
| Dec 31, 2025 | -2.27 Mn |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -958,146.34 |
| Mar 31, 2025 | -762,170.25 |
| Dec 31, 2024 | -1.13 Mn |
| Sep 30, 2024 | 10.29 Mn |
| Mar 31, 2018 | 46.97 Mn |
| Dec 31, 2017 | 51.67 Mn |
| Sep 30, 2017 | 44.33 Mn |
| Jun 30, 2017 | 9.17 Mn |
| Mar 31, 2017 | -687,006.12 |
| Dec 31, 2016 | 69.77 Mn |
| Sep 30, 2016 | 44.07 Mn |
| Jun 30, 2016 | 18.89 Mn |
| Mar 31, 2016 | -3.26 Mn |
| Dec 31, 2013 | -16,124.88 |
| Sep 30, 2013 | -16,126.93 |
| Jun 30, 2013 | -17,972.06 |